NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.
Metrics to compare | NRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.9x | −2.1x | −0.5x | |
PEG Ratio | 1.78 | 0.00 | 0.00 | |
Price/Book | 30.5x | −0.1x | 2.6x | |
Price / LTM Sales | - | 5.6x | 3.3x | |
Upside (Analyst Target) | 265.5% | 324.5% | 43.5% | |
Fair Value Upside | Unlock | 8.0% | 6.8% | Unlock |